Maravai LifeSciences (MRVI) Stock Forecast, Price Target & Predictions
MRVI Stock Forecast
Maravai LifeSciences stock forecast is as follows: an average price target of $19.00 (represents a 310.37% upside from MRVI’s last price of $4.63) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
MRVI Price Target
The average price target for Maravai LifeSciences (MRVI) is $19.00 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $25.00 to $10.00. This represents a potential 310.37% upside from MRVI's last price of $4.63.
MRVI Analyst Ratings
According to 7 Wall Street analysts, Maravai LifeSciences's rating consensus is 'Buy'. The analyst rating breakdown for MRVI stock is 0 'Strong Buy' (0.00%), 5 'Buy' (71.43%), 2 'Hold' (28.57%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Maravai LifeSciences Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 09, 2024 | Catherine Schulte | Robert W. Baird | $10.00 | $8.87 | 12.74% | 115.98% |
| Dec 14, 2022 | - | Deutsche Bank | $25.00 | $15.03 | 66.31% | 439.96% |
| Dec 07, 2022 | - | RBC Capital | $22.00 | $12.50 | 76.00% | 375.16% |
The latest Maravai LifeSciences stock forecast, released on May 09, 2024 by Catherine Schulte from Robert W. Baird, set a price target of $10.00, which represents a 12.74% increase from the stock price at the time of the forecast ($8.87), and a 115.98% increase from MRVI last price ($4.63).
Maravai LifeSciences Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $10.00 |
| Last Closing Price | $4.63 | $4.63 | $4.63 |
| Upside/Downside | -100.00% | -100.00% | 115.98% |
In the current month, the average price target of Maravai LifeSciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Maravai LifeSciences's last price of $4.63. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 08, 2024 | UBS | Underperform | Underperform | Hold |
| Oct 08, 2024 | Wells Fargo | Equal-Weight | Equal-Weight | Hold |
| Aug 27, 2024 | Wells Fargo | - | Overweight | Initialise |
| Aug 13, 2024 | Morgan Stanley | Overweight | Equal-Weight | Downgrade |
| Aug 08, 2024 | UBS | Neutral | Neutral | Hold |
| Jun 03, 2024 | Jefferies | Buy | Buy | Hold |
| May 29, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Feb 23, 2024 | William Blair | Outperform | Outperform | Hold |
| Dec 12, 2023 | Bank of America Securities | - | Buy | Upgrade |
| Jan 05, 2023 | UBS | - | Neutral | Downgrade |
Maravai LifeSciences's last stock rating was published by UBS on Oct 08, 2024. The company gave MRVI a "Underperform" rating, the same as its previous rate.
Maravai LifeSciences Financial Forecast
Maravai LifeSciences Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $66.86M | $68.91M | $79.03M | $204.71M | $191.26M | $242.73M | $244.29M | $228.44M | $204.81M | $217.78M | $148.21M | $98.35M |
| Avg Forecast | $70.01M | $68.33M | $62.89M | $57.48M | $69.11M | $68.67M | $67.98M | $64.81M | $56.65M | $67.55M | $71.92M | $60.54M | $64.37M | $75.47M | $71.10M | $80.00M | $204.93M | $195.11M | $233.22M | $232.29M | $208.09M | $201.50M | $194.81M | $138.49M | $89.60M |
| High Forecast | $74.91M | $73.11M | $67.29M | $61.50M | $73.94M | $73.47M | $72.73M | $69.10M | $59.59M | $67.62M | $72.06M | $60.54M | $67.04M | $79.55M | $76.07M | $85.59M | $219.27M | $195.11M | $233.22M | $232.29M | $208.09M | $201.50M | $194.81M | $138.49M | $89.60M |
| Low Forecast | $61.75M | $60.27M | $55.47M | $50.70M | $60.96M | $60.57M | $59.96M | $56.61M | $52.29M | $67.48M | $71.78M | $60.54M | $59.27M | $72.06M | $62.71M | $70.56M | $180.76M | $195.11M | $233.22M | $232.29M | $208.09M | $201.50M | $194.81M | $138.49M | $89.60M |
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 6 | 8 | 4 | 3 | 3 | 6 | 10 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.89% | 0.97% | 0.99% | 1.00% | 0.98% | 1.04% | 1.05% | 1.10% | 1.02% | 1.12% | 1.07% | 1.10% |
Maravai LifeSciences's average Quarter revenue forecast for Dec 23 based on 6 analysts is $64.37M, with a low forecast of $59.27M, and a high forecast of $67.04M. MRVI's average Quarter revenue forecast represents a -3.73% decrease compared to the company's last Quarter revenue of $66.86M (Sep 23).
Maravai LifeSciences EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 6 | 8 | 4 | 3 | 3 | 6 | 10 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $-5.53M | $-8.76M | $8.75M | $112.50M | $116.90M | $171.63M | $174.75M | $83.87M | $88.74M | $76.31M | $52.62M | $28.23M |
| Avg Forecast | $45.47M | $44.37M | $40.84M | $37.33M | $44.88M | $44.59M | $44.14M | $42.09M | $36.79M | $43.87M | $46.71M | $39.32M | $41.81M | $49.01M | $46.17M | $51.95M | $75.27M | $83.74M | $100.10M | $74.87M | $89.31M | $86.49M | $83.61M | $40.09M | $38.46M |
| High Forecast | $48.65M | $47.48M | $43.70M | $39.94M | $48.02M | $47.71M | $47.23M | $44.88M | $38.70M | $43.92M | $46.80M | $39.32M | $43.54M | $51.66M | $49.40M | $55.59M | $90.32M | $83.74M | $100.10M | $89.84M | $89.31M | $86.49M | $83.61M | $48.11M | $38.46M |
| Low Forecast | $40.10M | $39.14M | $36.02M | $32.92M | $39.59M | $39.33M | $38.94M | $36.77M | $33.96M | $43.83M | $46.61M | $39.32M | $38.49M | $46.80M | $40.73M | $45.82M | $60.21M | $83.74M | $100.10M | $59.90M | $89.31M | $86.49M | $83.61M | $32.07M | $38.46M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.11% | -0.19% | 0.17% | 1.49% | 1.40% | 1.71% | 2.33% | 0.94% | 1.03% | 0.91% | 1.31% | 0.73% |
9 analysts predict MRVI's average Quarter EBITDA for Jun 23 to be $46.17M, with a high of $49.40M and a low of $40.73M. This is 427.91% upper than Maravai LifeSciences's previous annual EBITDA (Mar 23) of $8.75M.
Maravai LifeSciences Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 6 | 8 | 4 | 3 | 3 | 6 | 10 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-6.46M | $-6.54M | $-1.35M | $87.43M | $99.65M | $156.72M | $146.86M | $127.11M | $54.27M | $49.08M | $23.25M | $13.13M |
| Avg Forecast | $-1.54M | $-2.13M | $-3.67M | $-5.29M | $-1.51M | $-1.78M | $-2.31M | $-3.19M | $-5.81M | $-1.18M | $142.83K | $62.52M | $-1.63M | $785.91K | $1.80M | $56.83M | $50.10M | $44.78M | $61.68M | $51.67M | $52.26M | $47.78M | $42.89M | $17.71M | $14.47M |
| High Forecast | $-1.30M | $-1.80M | $-3.11M | $-4.48M | $-1.28M | $-1.51M | $-1.95M | $-2.70M | $-2.91M | $-1.00M | $155.82K | $75.02M | $-1.38M | $1.57M | $1.97M | $68.20M | $60.12M | $44.78M | $61.68M | $62.00M | $52.26M | $47.78M | $42.89M | $21.25M | $14.47M |
| Low Forecast | $-1.68M | $-2.32M | $-4.00M | $-5.77M | $-1.65M | $-1.94M | $-2.52M | $-3.48M | $-7.26M | $-1.29M | $120.93K | $50.01M | $-1.78M | $-785.91K | $1.53M | $45.47M | $40.08M | $44.78M | $61.68M | $41.33M | $52.26M | $47.78M | $42.89M | $14.17M | $14.47M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -8.22% | -3.63% | -0.02% | 1.75% | 2.23% | 2.54% | 2.84% | 2.43% | 1.14% | 1.14% | 1.31% | 0.91% |
Maravai LifeSciences's average Quarter net income forecast for Mar 23 is $56.83M, with a range of $45.47M to $68.20M. MRVI's average Quarter net income forecast represents a -35.00% decrease compared to the company's last Quarter net income of $87.43M (Dec 22).
Maravai LifeSciences SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 6 | 8 | 4 | 3 | 3 | 6 | 10 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $38.86M | $35.38M | $38.67M | $37.20M | $30.80M | $28.06M | $33.20M | $25.58M | $25.19M | $24.09M | $23.24M | $41.62M |
| Avg Forecast | $20.51M | $20.02M | $18.43M | $16.84M | $20.25M | $20.12M | $19.92M | $18.99M | $16.60M | $19.79M | $21.07M | $31.04M | $18.86M | $22.12M | $20.83M | $28.22M | $22.96M | $53.54M | $64.00M | $25.65M | $57.10M | $55.29M | $53.46M | $17.70M | $24.59M |
| High Forecast | $21.95M | $21.42M | $19.72M | $18.02M | $21.67M | $21.53M | $21.31M | $20.25M | $17.46M | $19.82M | $21.12M | $37.25M | $19.64M | $23.31M | $22.29M | $33.86M | $27.55M | $53.54M | $64.00M | $30.79M | $57.10M | $55.29M | $53.46M | $21.25M | $24.59M |
| Low Forecast | $18.09M | $17.66M | $16.25M | $14.86M | $17.86M | $17.75M | $17.57M | $16.59M | $15.32M | $19.77M | $21.03M | $24.83M | $17.37M | $21.11M | $18.38M | $22.58M | $18.36M | $53.54M | $64.00M | $20.52M | $57.10M | $55.29M | $53.46M | $14.16M | $24.59M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.76% | 1.70% | 1.37% | 1.62% | 0.58% | 0.44% | 1.29% | 0.45% | 0.46% | 0.45% | 1.31% | 1.69% |
Maravai LifeSciences's average Quarter SG&A projection for Dec 23 is $18.86M, based on 6 Wall Street analysts, with a range of $17.37M to $19.64M. The forecast indicates a -51.47% fall compared to MRVI last annual SG&A of $38.86M (Sep 23).
Maravai LifeSciences EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 6 | 8 | 4 | 3 | 3 | 6 | 10 | 9 | 9 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.05 | $-0.05 | $-0.01 | $0.66 | $0.76 | $1.19 | $1.12 | $0.97 | $0.46 | $0.44 | $0.24 | $0.32 |
| Avg Forecast | $-0.01 | $-0.02 | $-0.03 | $-0.04 | $-0.01 | $-0.01 | $-0.02 | $-0.02 | $-0.04 | $-0.01 | - | $-0.03 | $-0.01 | $0.01 | $0.01 | $0.03 | $0.34 | $0.33 | $0.45 | $0.44 | $0.38 | $0.35 | $0.32 | $0.21 | $0.11 |
| High Forecast | $-0.01 | $-0.01 | $-0.02 | $-0.03 | $-0.01 | $-0.01 | $-0.01 | $-0.02 | $-0.02 | $-0.01 | - | $-0.02 | $-0.01 | $0.01 | $0.01 | $0.03 | $0.37 | $0.33 | $0.45 | $0.44 | $0.38 | $0.35 | $0.32 | $0.21 | $0.11 |
| Low Forecast | $-0.01 | $-0.02 | $-0.03 | $-0.04 | $-0.01 | $-0.01 | $-0.02 | $-0.02 | $-0.05 | $-0.01 | - | $-0.03 | $-0.01 | $-0.01 | $0.01 | $0.03 | $0.29 | $0.33 | $0.45 | $0.44 | $0.38 | $0.35 | $0.32 | $0.21 | $0.11 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -8.83% | -3.90% | -0.32% | 1.93% | 2.31% | 2.62% | 2.55% | 2.52% | 1.31% | 1.39% | 1.14% | 3.05% |
According to 9 Wall Street analysts, Maravai LifeSciences's projected average Quarter EPS for Mar 23 is $0.03, with a low estimate of $0.03 and a high estimate of $0.03. This represents a -95.15% decrease compared to MRVI previous annual EPS of $0.66 (Dec 22).
Maravai LifeSciences Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| MRVI | Maravai LifeSciences | $4.63 | $19.00 | 310.37% | Buy |
| ARQT | Arcutis Biotherapeutics | $10.09 | $31.00 | 207.23% | Buy |
| APLS | Apellis Pharmaceuticals | $28.99 | $74.50 | 156.99% | Buy |
| ABUS | Arbutus Biopharma | $3.49 | $8.50 | 143.55% | Buy |
| RARE | Ultragenyx Pharmaceutical | $45.13 | $106.93 | 136.94% | Buy |
| LEGN | Legend Biotech | $38.40 | $82.69 | 115.34% | Buy |
| IMVT | Immunovant | $25.22 | $42.83 | 69.83% | Buy |
| DNLI | Denali Therapeutics | $24.34 | $40.00 | 64.34% | Buy |
| CYTK | Cytokinetics | $51.09 | $83.23 | 62.91% | Buy |
| FOLD | Amicus Therapeutics | $9.52 | $15.25 | 60.19% | Buy |
| ASND | Ascendis Pharma | $124.44 | $190.21 | 52.85% | Buy |
| HRMY | Harmony Biosciences | $32.48 | $48.86 | 50.43% | Buy |
| AKRO | Akero Therapeutics | $31.03 | $46.00 | 48.24% | Buy |
| ROIV | Roivant Sciences | $11.31 | $16.21 | 43.32% | Buy |
| EWTX | Edgewise Therapeutics | $31.51 | $45.00 | 42.81% | Buy |
| PTGX | Protagonist Therapeutics | $38.65 | $50.00 | 29.37% | Buy |
| HALO | Halozyme Therapeutics | $44.81 | $57.00 | 27.20% | Buy |
| INCY | Incyte | $70.56 | $84.56 | 19.84% | Buy |
| KRYS | Krystal Biotech | $177.85 | $191.00 | 7.39% | Buy |
| ALEC | Alector | $3.85 | $4.00 | 3.90% | Buy |
| INSM | Insmed | $73.72 | $76.25 | 3.43% | Buy |
| AGIO | Agios Pharmaceuticals | $54.41 | $48.00 | -11.78% | Buy |
| ARGX | argenx SE | $574.54 | $475.14 | -17.30% | Buy |
| CERE | Cerevel Therapeutics | $44.96 | $33.50 | -25.49% | Buy |
| RXDX | Prometheus Biosciences | $199.92 | $138.57 | -30.69% | Buy |